USANA Health Sciences (NYSE:USNA) Stock Crosses Above 200 Day Moving Average – Here’s Why

USANA Health Sciences, Inc. (NYSE:USNA)’s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $19.43 and traded as high as $19.78. USANA Health Sciences shares last traded at $19.0660, with a volume of 89,336 shares trading hands.

Analysts Set New Price Targets

A number of analysts have weighed in on USNA shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

USANA Health Sciences Stock Performance

The stock has a market cap of $350.74 million, a P/E ratio of 40.43, a price-to-earnings-growth ratio of 0.72 and a beta of 0.76. The firm’s fifty day simple moving average is $18.75 and its 200-day simple moving average is $19.41.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Analysts predict that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the sale, the director owned 4,230 shares in the company, valued at $75,843.90. This represents a 36.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 18,718 shares of company stock valued at $354,565. Insiders own 0.82% of the company’s stock.

Institutional Trading of USANA Health Sciences

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC grew its holdings in USANA Health Sciences by 82.8% in the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company’s stock worth $589,000 after purchasing an additional 9,894 shares during the period. Empowered Funds LLC acquired a new stake in shares of USANA Health Sciences in the 1st quarter valued at about $687,000. Russell Investments Group Ltd. grew its stake in shares of USANA Health Sciences by 31.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company’s stock valued at $408,000 after buying an additional 3,198 shares during the period. Quantbot Technologies LP increased its position in USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after buying an additional 646 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in USANA Health Sciences in the 2nd quarter valued at about $422,000. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.